Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Currently there is no approved pharmacotherapy for amphetamine dependence. Recent human laboratory studies have demonstrated that naltrexone modulates some of the reinforcing effects of amphetamine. The aim of this study was to investigate the efficacy of naltrexone in comparison with placebo in reducing relapse to amphetamine use in amphetamine-dependent patients. METHOD: Eighty patients who met DSM-IV criteria for amphetamine dependence were randomized to 12 weeks of double-blind naltrexone (50 mg) or placebo treatment. Patients visited the clinic twice weekly to receive medication and relapse prevention therapy and leave urine samples, which were analyzed for drug toxicology and for assessing adherence to medication via detection of naltrexone's metabolite (6-beta-naltrexol). The main outcome measure was abstinence from amphetamine use, as indicated by the total number of negative amphetamine urine samples during 12 weeks of treatment. All missing urine samples were defined for the analysis as positive for amphetamine. RESULTS: Overall, 55 patients (68.8%) completed the trial. The intention-to-treat analysis showed that the naltrexone group had a significantly higher number of amphetamine-negative urine samples compared with the placebo group. Survival analyses showed that the treatment groups differed in rate of continuous abstinence, in both the intention-to-treat and completer samples, in favor of naltrexone treatment. There was a significant reduction in craving levels and self-reported consumption of amphetamine in the naltrexone group compared with the placebo group. Treatment with naltrexone was well tolerated in this sample. CONCLUSIONS: This trial demonstrated the efficacy of naltrexone in reducing amphetamine use in amphetamine-dependent individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A randomized controlled trial of naltrexone (50mg/d) for amphetamine use disorder showed significantly greater reductions in craving ratings compared to placebo (50).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [50]
In the citing paper
“Significantly greater reduction in craving”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Jayaram- Lindström et al., 2008
Citations
Cites
1 retracted
Treatment for amphetamine dependence and abuse
Srisurapanont, M., Jarusuraisin, N., & Kittirattanapaiboon, P. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003022 · Cited by 77
RetractedThe fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
A psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Central Catecholamine Neuron Systems: Anatomy and Physiology of the Dopamine Systems
Moore, R. Y., & Bloom, F. E. (1978) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.01.030178.001021 · Cited by 926
Measuring Alcohol Consumption: Psychosocial and Biochemical Methods
(1992) · Humana Press eBooks · doi:10.1007/978-1-4612-0357-5 · Cited by 504
The development of a cocaine craving questionnaire
Tiffany, S. T., Singleton, E., Haertzen, C. A., & Henningfield, J. E. (1993) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(93)90042-o · Cited by 435
Neurobiology of addiction: treatment and public policy ramifications
Dackis, C., & O'Brien, C. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1431 · Cited by 267
Naltrexone-induced alterations in human ethanol intoxication
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1463 · Cited by 254 · cited 1×
“It has been established (13, 19, 20) that the therapeutic effect of naltrexone does not result from any nonspecific effect, such as a pharmacokinetic interaction.”
BackgroundKing, A. C., Volpicelli, J. R., Frazer, A., & O'Brien, C. P. (1997) · Psychopharmacology · doi:10.1007/s002130050156 · Cited by 227 · cited 1×
“It has been established (13, 19, 20) that the therapeutic effect of naltrexone does not result from any nonspecific effect, such as a pharmacokinetic interaction.”
BackgroundCroop, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240090013 · Cited by 211
Research works printed but not linked: 5
- United Nations Office on Drugs and Crime, 2005, Drug Report
- Swedish Council for Information on Alcohol and Other Drugs, 2006, Drug Trends in Sweden
- Srisurapanont M, 2001, Cochrane Database Syst Rev, 4, D003022
- Sobell LC, 1992, Measuring Alcohol Consumption, 44
- Lee MC, 1988, J Nucl Med, 29, 1207
Cited by
Items 101–185 of 185
Kaka, G., Rahmanzade, R., Safee, F., & Haghparast, A. (2014) · PubMed Central · Cited by 8
Kelty, E. A., Thomson, K., Carlstein, S., Sinclair, R., & Hulse, G. K. (2013) · American Journal on Addictions · doi:10.1111/j.1521-0391.2013.00320.x · Cited by 7
Hulse, A. S. R. G. K. (2014) · Journal of Forensic Toxicology and Pharmacology · doi:10.4172/2325-9841.1000126 · Cited by 7
Human Brain Imaging of Opioid Receptors
Ghitza, U. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418677-4.00004-x · Cited by 7
Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy
Sterling, J. A. (2007) · Hospital Pharmacy · doi:10.1310/hpj4206-578 · Cited by 7
Gao, Z., Winhusen, T. M., Gorenflo, M. P., Dorney, I., Ghitza, U. E., Kaelber, D. C., & Xu, R. (2024) · Addiction · doi:10.1111/add.16715 · Cited by 8
A Narrative Review of the Pathophysiology and Treatment of Methamphetamine-Associated Psychosis
Stacy, P. D., Frantz, J., Miller, G., Merrill, B., & Gainer, D. M. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01323-y · Cited by 7
Shariatirad, S., Mahjoub, A., Haqiqi, A., Hemami, M. R., Tofighi, B., Ekhtiari, H., & Effatpanah, M. (2018) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs.11529 · Cited by 5
“Bupropion and naltrexone have demonstrated some promising findings in reducing cravings for amphetamine in randomized controlled trials (8, 9).”
BackgroundJones, J. D., Mumtaz, M., Vadhan, N. P., Martinez, S., Pramanik, S., Manubay, J. M., Mogali, S., Perez, F., Castillo, F., Kranzler, H. R., et al. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000671 · Cited by 5
Crystal-Meth als Herausforderung für das Suchthilfesystem – Klinische Empfehlungen
Härtel-Petri, R. (2015) · Suchttherapie · doi:10.1055/s-0035-1559657 · Cited by 9
Stimulants: Caffeine, Cocaine, Amphetamine, and Other Stimulants
DeVido, J. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-33404-8_12 · Cited by 8
Treatment of Opioid Dependence
Saxon, A. J. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch005 · Cited by 5
Effect of add-on valproate on craving in methamphetamine depended patients: A randomized trial
Kheirabadi, G. R., Ghavami, M., Maracy, M. R., Salehi, M., & Sharbafchi, M. R. (2016) · Advanced Biomedical Research · doi:10.4103/2277-9175.187404 · Cited by 5
“In few studies, it is proven naltrexone,[37,38] bupropion,[39,40] and Modafinil effects[41,42] in reducing the desire to consume methamphetamine.”
BackgroundEffects of naltrexone on amphetamine choice in rhesus monkeys and rats.
Robinson, H. L., Moerke, M. J., Banks, M. L., & Negus, S. S. (2023) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000655 · Cited by 3
Bastien, G., McAnulty, C., Sharafi, H., Mahroug, A., Elkrief, L., Ziegler, D., Dubreucq, S., Juteau, L.-C., & Jutras‐Aswad, D. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001422 · Cited by 4
Clinical Aspects of Methamphetamine
Rawson, R. A., Gonzales, R. E., & Ling, W. W. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_22 · Cited by 5
Grimm, J. W. (2010) · Neuromethods · doi:10.1007/978-1-60761-934-5_12 · Cited by 4
Lam, L., Anand, S., Li, X., Tse, M. L., Zhao, J. X., & Chan, E. W. (2018) · Clinical Toxicology · doi:10.1080/15563650.2018.1529317 · Cited by 5
“In the first study [47], the severity of”
BackgroundMethodInfluentialComorbid substance use among persons with HIV and chronic pain
Lum, P. J., & Bruce, R. D. (2016) · Wiley eBooks · doi:10.1002/9781118777374.ch9 · Cited by 4
Medication Development for Amphetamine Dependence
Heinzerling, K. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398338-1.00048-8 · Cited by 5
Pharmacological and Integrated Treatments in Older Adults with Substance Use Disorders
Mannelli, P., Wu, L.-T. T., & Brady, K. T. (2014) · Wiley eBooks · doi:10.1002/9781118430965.ch20 · Cited by 3
The diagnosis and treatment of stimulant-related emergencies
Fries, A., Christ, M., Nickl, H., Spreer, M., Pilhatsch, M., & Petzold, J. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0158 · Cited by 4
Evidence-Based Practices for Co-occurring Addiction and Mental Illness
Yuodelis‐Flores, C., Iles-Shih, M., & Ries, R. K. (2022) · Springer eBooks · doi:10.1007/978-3-031-10239-4_25 · Cited by 3
Off-label medications for addictive disorders
Vanderhoof, T. S. (2023) · Current Psychiatry · doi:10.12788/cp.0384 · Cited by 2
Disorders due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_26 · Cited by 4
Tollison, S. J., Henderson, R. C., Baer, J. S., & Saxon, A. J. (2012) · Military Medicine · doi:10.7205/milmed-d-12-00126 · Cited by 2
Alcohol and Endogenous Opioids
Palm, S., & Nylander, I. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800213-1.00037-7 · Cited by 4
Opioid analgesics and narcotic antagonists
Ghodse, A. H., & Galea, S. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00008-8 · Cited by 2
Courtney, S. E., Roche, K. J., & London, K. S. (2015) · Cited by 2
Methamphetamine psychosis, the efficacy of atypical antipsychotics
Ardanı, A. R., & Nasab, A. M. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.17463/rcm.2015.01.003 · Cited by 2
Diagnosis and Management of Substance Use Disorders in Athletes
Walters, P., Hillier, B., Passetti, F., Soni, A., & Treasaden, I. H. (2021) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2021.06.001 · Cited by 4
Lodge, W., Biello, K. B., Valente, P. K., & Mimiaga, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_109 · Cited by 2
Evaluation of Naltrexone as a treatment for amphetamine dependence
Jayaram‐Lindström, N. (2007) · Figshare · Cited by 2
Self-citationDiagnosis and Management of Comorbid ADHD in Patients with Substance Use Disorders
Busch, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-72219-6_50 · Cited by 1
Fletcher, K., Ezard, N., Siefried, K. J., Macdonald, H., Acheson, L. S., Bedi, G., Guerin, A. A., Knock, E., Millard, M., May, R., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-092504 · Cited by 3
Theta burst stimulation (TBS) in methamphetamine use disorder: a meta-analysis and systematic review
Rakesh, G., Adams, T. G., Ballard, D. H., McLouth, C. J., & Rush, C. R. (2025) · Journal of Addictive Diseases · doi:10.1080/10550887.2025.2541165 · Cited by 1
Fakhri, A., Norouzi, S., Baghaei, S., Bitaraf, S., Amini, P., Mousavi, S., & Kasaei, M. H. S. (2025) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp-167514 · Cited by 1
Elkashef, A. M., & Montoya, I. D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3375-0_8 · Cited by 1
HIV in people who use drugs 5 Amphetamine-group substances and HIV
Colfax, G. N., Santos, G., Chu, P. L., Vittinghoff, E., Plüddemann, A., Kumar, S., & Hart, C. L. (2010) · Cited by 1
The effects of naltrexone on neural responses to methamphetamine cues
Courtney, K. E., Ghahremani, D. G., & Ray, L. A. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.08.141 · Cited by 1
“…was associated with reduced amphetamine (Jayaram-Lindstrom, Hammarberg, et al., 2008) and dexamphetamine craving in amphetamine dependent patients (Jayaram-Lindstrom et al., 2008), although no effect of naltrexone on craving was observed in individuals with dual dependence on heroin and…”
BackgroundPerinatal Methamphetamine Use: A Review of the Literature
Hickert, A., Rowley, B., & Doyle, M. (2021) · Psychiatric Annals · doi:10.3928/00485713-20210303-01 · Cited by 1
The Hypothesis of Subliminal Cue Reactivity in Addiction Revisited: An fMRI Study
Guterstam, J., Jayaram‐Lindström, N., Berrebi, J., Petrović, P., Ingvar, M., Fransson, P., & Franck, J. (2022) · European Addiction Research · doi:10.1159/000521344 · Cited by 2
Self-citationOutcome Measures in Medication Trials for Substance Use Disorders
McCann, D. J., Ramey, T., & Skolnick, P. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0041-x · Cited by 1
Crystal meth abuse: A pretty state of affairs
Goyal, N., & Kaur, G. (2023) · AIP conference proceedings · doi:10.1063/5.0115624 · Cited by 1
Integrative Approach to Stimulant-Use Disorder
Mitton, A. G., & Mooney, L. J. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780190275334.003.0007 · Cited by 1
Sevarino, K. A., & Shelby, B. C. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch80 · Cited by 1
Sustained-Release Opiate Blockers for Treating Heroin and Amphetamine Dependence
Penetar, D. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12020210 · Cited by 1
Promoting and Maintaining Engagement in Substance Abuse Treatment
Kunøe, N. (2020) · Wiley eBooks · doi:10.1002/9781119129530.ch22 · Cited by 1
Jayaram‐Lindström, N. (2017) · doi:10.26226/morressier.5971be87d462b80290b528ab · Cited by 1
Self-citationTurning on and off the cerebellum in drug-induced memory
Eixea, I. M., & Melchor Eixea, I. (2024) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14112.2024.428833 · Cited by 1
Recent Advances in Drug Development
Vocci, F. J. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_32
Horton, D. B. (2012) · UKnowledge (University of Kentucky)
Durbeej, N. (2014) · Figshare · Cited by 1
Amphetamine Derivatives as Appetite Suppressants
Freye, E. C. K. (2009) · Springer eBooks · doi:10.1007/978-90-481-2448-0_21
Evidence-Based Practices for Co-occurring Chemical Dependency and Mental Illness
Yuodelis‐Flores, C., Ries, R. K., & Bennett, W. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3149-7_23
Brain opioid mechanisms in amphetamine induced behaviours
Häggkvist, J. (2009) · Figshare · Cited by 1
Commentary on Konstenius et al. (2014): on medication development for stimulant addiction.
Shoptaw, S. (2014) · Addiction · doi:10.1111/add.12480
Adverse Events in the Removal of Naltrexone Implants
Sadleir, P. H. M., Gardner, A. I., & Hennessy, B. (2011) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1103900515
Pharmacotherapies for Drug Addiction
Gipson, C. D., & Kalivas, P. W. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00357
Can Naltrexone Reduce Amphetamine Abuse and Dependence
Yager, J. (2008) · Journal watch · doi:10.1056/jp200812010000001
Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China
Sun, H., Chen, H., Yang, F., Lü, L., & Kosten, T. R. (2013) · American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12116.x
Mattioli, T.-A. M. (2013) · QSpace (Queen's University Library)
Jayaram‐Lindström, N. (2017) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(17)31859-x
Self-citationSasiadek, J., Lowe, D. J. E., Rioux, S.-M., & George, T. P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-68309-8.00008-4
Ernst, F., Viohl, L., & Betzler, F. (2020) · Springer Reference Psychologie · doi:10.1007/978-3-642-55214-4_101-1 · Cited by 2
Current awareness in human psychopharmacology
(2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.973
Lodge, W., Biello, K. B., Valente, P. K., & Mimiaga, M. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_109-1 · Cited by 2
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01129-x
Novel Approaches for Treating Addiction
Acri, J. B., & Skolnick, P. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0048
Disorders Due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_26-1 · Cited by 1
Chapter 8. Trinity Combinations
(2023) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379989.lg08
Rakesh, G., Adams, T. G., Ballard, D. H., McLouth, C. J., & Rush, C. R. (2025) · medRxiv · doi:10.1101/2025.03.24.25324326
Carmody, T. J., Mayes, T. L., Jha, M. K., SHOPTAW, S. J., & Trivedi, M. H. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001533 · Cited by 1
Muhamad, N. A., Maamor, N. H., Rasat, M. A. M., Shah, T. P. N. T. B., Rosli, I. A., Leman, F. N., Jamalluddin, N. H., Misnan, N. S., Chemi, N. B., Abdullah, N., et al. (2025) · JMIR Research Protocols · doi:10.2196/64101
“Few studies have proposed naltrexone as a treatment for StUD and demonstrated a significant effect in reducing the consumption and craving for amphetamine [18-20].”
Graddy, R., & Rastegar, D. A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197796207.003.0008
Naltrexone blocks the sleep-disrupting effects of methamphetamine in male rhesus monkeys
Davis, P. G., Nascimento-Rocha, V., Rowlett, J. K., & Berro, L. F. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112911
Kampman, K. M. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg06
Recent Publications on Medications and Pharmacy
Sterling, J. A. (2008) · Hospital Pharmacy · doi:10.1310/hpj4312-1024
Hamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., Macpherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13141762
Hamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., Macpherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13141777
Hamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., Macpherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13141774
Hamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., MacPherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13141765
Hamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., Macpherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13141771
Chapter 9. Stimulant Use Disorder Among Older Adults
Wang, M. Z., Buchholz, J., & Saxon, A. J. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551968.lg09
Treatment Options in Methamphetamine Addiction and Withdrawal
Freye, E. C. K. (2009) · Springer eBooks · doi:10.1007/978-90-481-2448-0_20
Metadata
- Authors
- Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J.
- Venue
- American Journal of Psychiatry
- Published
- 2008-11
- Volume
- 165
- Issue
- 11
- Pages
- 1442-1448
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2116763568
- Cited by
- 185
- References
- 26
- Citations by year
- 2025: 11 · 2024: 8 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 12 · 2019: 5 · 2018: 11 · 2017: 11 · 2016: 9 · 2015: 17 · 2014: 18 · 2013: 15 · 2012: 16
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- naltrexone, amphetamine dependence, pharmacotherapy, relapse prevention, abstinence, craving, urine drug testing, medication adherence
- MeSH terms
- Adult, Amphetamine, Double-Blind Method, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Substance Withdrawal Syndrome, Substance Abuse Detection, Survival Analysis, Treatment Outcome, Amphetamine-Related Disorders, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.